Antithrombotics: From Aspirin to DOACs in Coronary Artery Disease and Atrial Fibrillation (Part 3/5).

Published

Journal Article (Review)

For secondary prevention of coronary artery disease (CAD), oral antiplatelet therapy is essential. In case of coronary intervention, temporary dual antiplatelet therapy is mandatory as well. Recently, low-dose oral anticoagulation has entered the CAD arena. Atrial fibrillation (AF) is often seen in CAD and vice versa. In most patients stroke prevention in AF consists of oral anticoagulation. In many cases of CAD in patients with AF, anticoagulation has to be combined with antiplatelet agents (so called, dual pathway antithrombotic therapy). Excess bleeding in these conditions is a rapidly rising problem. This review addresses the antithrombotic options in CAD alone, in AF alone, and in their combination, when either an invasive or a noninvasive approach has been chosen.

Full Text

Duke Authors

Cited Authors

  • Verheugt, FWA; Ten Berg, JM; Storey, RF; Cuisset, T; Granger, CB

Published Date

  • August 6, 2019

Published In

Volume / Issue

  • 74 / 5

Start / End Page

  • 699 - 711

PubMed ID

  • 31277840

Pubmed Central ID

  • 31277840

Electronic International Standard Serial Number (EISSN)

  • 1558-3597

Digital Object Identifier (DOI)

  • 10.1016/j.jacc.2019.02.080

Language

  • eng

Conference Location

  • United States